Sanguine European Limited - Period Ending 2019-12-31
Sanguine European Limited - Period Ending 2019-12-31
Registration number:
Sanguine European Limited
for the Year Ended 31 December 2019
Sanguine European Limited
Contents
|
Company Information |
|
|
Balance Sheet |
|
|
Notes to the Unaudited Financial Statements |
Sanguine European Limited
Company Information
|
Director |
E Sproston |
|
Registered office |
|
Sanguine European Limited
(Registration number: 10646151)
Balance Sheet as at 31 December 2019
|
2019 |
2018 |
|
|
Fixed assets |
|
|
|
Current assets |
|
|
|
Creditors: Amounts falling due within one year |
( |
( |
|
Net current assets |
|
|
|
Total assets less current liabilities |
|
|
|
Creditors: Amounts falling due after more than one year |
( |
( |
|
|
|
|
|
Capital and reserves |
|
|
|
General information |
The company is a private company limited by share capital, incorporated in England and Wales.
The address of its registered office is:
These financial statements were authorised for issue by the
Basis of preparation
The financial statements have been prepared under the historical cost convention and in accordance with FRS 105 'The Financial Reporting Standard applicable to the Micro-entities Regime'.
|
Staff numbers |
The average number of persons employed by the company (including the director) during the year, was
These financial statements have been prepared in accordance with the micro-entity provisions of the Companies Act 2006 and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
Sanguine European Limited
(Registration number: 10646151)
Balance Sheet as at 31 December 2019
For the financial year ending 31 December 2019 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
|
• |
|
|
• |
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. |
Approved and authorised by the
.........................................
Director